GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Other Operating Expense

BNR (Burning Rock Biotech) Other Operating Expense : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Other Operating Expense?

Burning Rock Biotech's Other Operating Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Burning Rock Biotech's quarterly Other Operating Expense increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then declined from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Burning Rock Biotech's annual Other Operating Expense declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).


Burning Rock Biotech Other Operating Expense Historical Data

The historical data trend for Burning Rock Biotech's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech Other Operating Expense Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial - - - - -

Burning Rock Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Burning Rock Biotech Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burning Rock Biotech Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Burning Rock Biotech Business Description

Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.